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Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is the most frequently encountered tumor
in the adult kidney. Many factors are known to take part in the development and progression of
this tumor. Nuclear factor kappa B (NF-κB) is a family of the genes that includes five members
acting in events such as inflammation and apoptosis. In this study, the role of NF-κB (p50 subunit)
in ccRCC and its relation to angiogenesis and apoptosis were investigated.
Methods: Formalin-fixed and paraffin embedded tissue blocks from 40 patients with ccRCC were
studied. Expressions of NF-κB (p50), VEGF, EGFR, bc1-2 and p53 were detected
immunohistochemically. The relationship of NF-κB with these markers and clinicopathological
findings were evaluated.
Results: The expression of NF-κB was detected in 35 (85%), VEGF in 37 (92.5%), EGFR in 38
(95%), bc1-2 in 33 (82.5%) and p53 in 13 (32.5%) of 40 ccRCC patients. Statistical analyses revealed
a significant relation between NF-κB expression and VEGF (p = 0.001), EGFR (p = 0.004), bc1-2 (p
= 0.010) and p53 (p = 0.037). There was no significant correlation between NF-κB and such
parameters as tumor grade, stage, age and sex.
Conclusion: The results of this study indicated that in ccRCC cases NF-κB was associated with
markers of angiogenesis and apoptosis such as VEGF, EGFR, bc1-2 and p53. In addition, the results
did not only suggest a close relationship between NF-κB and VEGF, EGFR, bc1-2 and p53 in ccRCC,
but also indicate that NF-κB was a potential therapeutic target in the treatment of ccRCC resistant
to chemotherapy.
Background
Renal cell carcinoma (RCC) is the most common malig-
nant tumor of the adult kidney, accounting for 3% of all
adult malignancies [1]. Clear cell renal cell carcinoma
(ccRCC) accounts for approximately 70% to 80% of all
cases of RCC [1,2]. In about two thirds of the patients with
RCC, the disease is localized. Localized disease can be
treated with radical or partial nephrectomy, and a vast
majority is cured with surgery, but the prognosis is poor
once the disease advances. The therapeutic options for
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such patients are few because chemotherapy is ineffective
[2]. Nuclear factor kappa B (NF-κB) is a family of tran-
scription factors, the functions of which are very well
known in apoptosis and inflammation [3,4]. In normal
cells NF-κB activation is regulated tightly. Normally, NF-
κB can be activated by an appropriate stimulus and
returns to the inactive status after the transcription in the
target genes have been completed. In tumoral cells, differ-
ent types of molecular alterations may result in damaged
regulation of NF-κB activation. The resulting alterations
participate in the development and progression of cancer
[5-10]. Previous studies have shown the role of NF-κB in
hematological or solid (like lung, gastric and prostate)
tumors [11-17]. There is evidence for the role of NF-κB in
RCC. Oya et al. demonstrated that increased NF-κB activ-
ity is associated with the development and progression of
RCC [18]. Vascular endothelial growth factor (VEGF) is a
strong stimulator of the mitogenic activity in the endothe-
lial cells. There have been many studies demonstrating the
prognostic importance of angiogenesis in various solid
tumors [19]. High VEGF expression, increased microvas-
cular density and advanced stage in RCCs usually indicate
a poor prognosis [20-24]. Numerous studies have shown
the association of EGFR with tumor proliferation, inva-
siveness and angiogenesis [25]. EGFR, which indicates a
poor prognosis in many tumors, has also been shown to
play a role in the development and progression of RCCs
[26]. Furthermore, high EGFR levels are frequently associ-
ated with high grade tumors, indicative of a poor progno-
sis [26]. Tumor suppressor gene, p53, helps to repair
damage in the DNA during the cell cycle and/or to direct
the cell to apoptosis. As a result of mutations in the p53
gene, responsible for the development of many tumors,
damaged cells may escape from apoptosis. In RCCs, high
p53 levels are associated with an advanced tumor and
poor prognosis [27,28]. bc1-2 is an intracellular mem-
brane protein which is well known to play a role in the
inhibition of apoptosis in many types of cancer. It is com-
monly thought that bc1-2, which has an antiapoptotic
activity, may be effective in increased resistance to chem-
otherapy in advanced stage RCCs [27-29]. There is little
known about the association of NF-κB with RCCs [30].
The aim of this study was to investigate the relation
between the p50 subunit of NF-κB and the factors like
apoptosis and angiogenesis, which affect tumor develop-
ment and progression in the frequently encountered adult
renal tumors, ccRCCs. Detection of a relation between
important growth factors and various genes like VEGF,
EGFR, p53 and bc1-2 and NF-κB activation will help to
enhance the effectiveness of the available therapies and to
develop new treatment modalities in the course of cura-
tive efforts for RCCs, which are considered as chemoresist-
ant tumors [31,32]. NF-κB is likely to be incorporated into
routine pathological investigations for RCCs and some
other tumors in the future. Another aim of this study was
to provide support for the use and standardization of
immunohistochemical techniques widely used to investi-
gate NF-κB status either in clinical practice or for research
in the pathology laboratories.
Methods
Patients
Forty patients who underwent radical or partial nephrec-
tomy for ccRCC at Adnan Menderes University Hospital
from 2002 to 2007 were included in the study. Data about
sex, age, tumor size, TNM stage and Fuhrman's nuclear
grade were obtained. None of the patients received treat-
ment for cancer before surgery. All specimens were re-
evaluated before the current study by two pathologists.
Paraffin-embedded specimens that contained normal
renal tissue together with the tumoral tissue were selected
for immunohistochemical analysis.
Immunohistochemistry
First, 4 μm thick slices taken from the selected paraffin
embedded blocks were placed on positively charged slides
and deparafinized with xylene and rehydrated with etha-
nol. Second, all were washed with 0.1% Tris-buffered
saline (TBS) three times for 5 minutes. They were kept in
0.3% hydrogen peroxidase for 20 minutes for the block-
age of endogenous peroxidase activity. Third, the slices
were rinsed with TBS three times for 5 minutes. For anti-
gen retrieval, the slides were placed in a sodium citrate
buffer and left in the microwave oven at 700-W for 10
minutes. Fourth, they were cooled to room temperature
and washed with TBS three times for 5 minutes. Fifth,
non-specific binding was blocked with 10% normal rab-
bit serum for 1 hour. Sixth, the slices were incubated with
primary antibodies rabbit polyclonal NF-κB/p50 (1:50
dilution, RB-1648; NeoMarkers, Fremont, CA, USA),
VEGF (ready solution for use, RB-9031; NeoMarkers, Fre-
mont, CA, USA), EGFR (ready solution for use, MS-378;
NeoMarkers, Fremont, CA, USA), p53 (ready solution for
use, MS-738; NeoMarkers, Fremont, CA, USA) and bcl-2
(ready solution for use, MS-123; NeoMarkers, Fremont,
CA, USA) for 1 hour. After the slides were rinsed with TBS
three times for 5 minutes, they were exposed to biotin free
horseradish peroxidase (HRP) enzyme-labeled polymer
(EnVision plus detection system, ChemMateTM EnVision
+/HRP Rb&Mo, DAKO, Hamburg, Germany) for 30 min-
utes. Seventh, the slides were rinsed again in TBS three
times for 5 minutes. Eight, 3,3'-diaminobenzidine
(DAKO) chromogen substrate was added. Last, the slides
were rinsed under tap water and countered with Mayer's
haematoxyline, dehydrated and mounted. For the nega-
tive control, the slides were incubated with TBS without
the primary antibody. The slides known to be positively
immunostained were used as positive controls.Journal of Experimental & Clinical Cancer Research 2008, 27:53 http://www.jeccr.com/content/27/1/53
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Evaluation of immunostaining
Firstly, the slides were examined at low magnification
(×100) and areas containing the highest density of stained
markers were chosen as "hot spot" areas and were evalu-
ated at high magnification (×200). The staining cell ratio
was determined by counting at least 200 cells. A staining
percentage of 10% or above was accepted to be positive
for all the markers. The scoring was accomplished accord-
ing to the degree of staining in different magnifications as
in the following: "weak" staining, visible at × 200; "mod-
erate" staining, visible at × 100 and "strong" staining visi-
ble at × 40.
Statistical analysis
Chi-square test for trend was used to assess the differential
expression of markers in malignant and non-malignant
kidney tissues. Spearman's rank correlation coefficient
was used to determine the correlation between ink pat-
terns of markers in RCC. P < 0.05 was considered signifi-
cant. All statistical analyses were performed with SPSS
(Windows version 13.0, SPSS Inc. Chicago, IL, USA).
Results
Clinicopathologic characteristics of the patients are sum-
marized in Table 1.
NF-κB staining was detected within the cytoplasm and
nuclei of the tumoral cells. The degree of nuclear staining
decreased towards the central areas of the tumor whereas
the most prominent nuclear staining was seen in the areas
adjacent to the non-tumoral renal tissue (Figure 1A).
There was prominent cytoplasmic and nuclear staining
within the histiocytes in the tumoral area (Figure 1B).
While various degrees of staining were detected in 34
patients (85%) with NF-κB, there was no staining in 6
patients (15%). A strong (+++) positive staining was
present in 19 patients. The staining was moderate in 10
patients and weak in 5 patients. The majority of the
tumors that showed a weak staining were stage I tumors
(Figure 2A–B). In 22 patients there was also a weak cyto-
plasmic staining in the tubular cells of the non-tumoral
renal cells (Figure 2A). While there was no glomerular
staining, there was some background staining within the
interstitial areas.
VEGF staining was present within the cytoplasm of the
tumor cells (Figure 1C, 2C). The staining degree was weak
to moderate in most of the patients. Staining was present
in 37 patients (92.5%), but there was none in 3 patients
(7.5%). In 18 patients, a weak staininig with VEGF was
present in tubules of the non-tumoral renal tissues. No
glomerular or interstitial staining was detected. The only
positive correlation was between VEGF and NF-κB. The
tumour cell membranes were stained with EGFR. In 6
patients tubular cells of the non-tumoral tissue were also
stained. No glomerular and interstitial staining was
present. There was staining with EGFR in 38 (95%)
patients, whereas no staining was present in 2 (5%)
patients. The staining was moderate in the majority of the
patients (Figure 1D, 2D). Apart from NF-κB, EGFR stain-
ing was also positively correlated with p53 (r = 0,370, p =
0.034). There were no other significant correlations with
any other parameters. We found cytoplasmic staining
with bc1-2 (Figure 1E, 2E). While there was no staining in
7 patients (17.5%), 33 patients (82.5%) displayed a posi-
tive staining. The degree of staining was predominantly
moderate. In 34 patients we detected staining in the non-
tumoral spaces. It was marked within the tubular epithe-
lial and interstitial inflammatory cells. p53 staining was
found to be within the nuclei of the tumor cells (Figure
1F, 2F). Thirteen patients (32.5%) displayed staining,
whereas 27 patients (67.5%) showed no staining. The
degree of the staining was predominantly weak. There was
also some staining within the tubular epithelia in the non-
tumoral area. There was neither glomerular nor interstitial
staining.
Immunohistochemical staining properties of NF-κB,
EGFR, VEGF, bcl-2 and p53 are shown in Table 2.
There was a significant positive correlation between the
staining degree of NF-κB and VEGF (r = 0,516, p = 0,001),
EGFR (r = 0,448, p = 0,004), bcl-2 (r = 0,403, p = 0,010)
and p53 (r = 0,332, p = 0,037). No correlation between
the NF-κB staining degree and age, sex, tumor size, TNM
stage and Fuhrmans' grade was established.
Table 1: Patients characteristics (n = 40)
n (%)
Age (year)
Range 35–85
Median 63
Sex
Male 30 (75)
Female 10 (25)
Tumor size (cm)
Range 1–20
Median 5.75
T stage
T1 21 (52.5)
T2 11 (27.5)
T3 7 (17.5)
T4 1 (2.5)
Fuhrmans' Grade
G1 13 (32.5)
G2 20 (50)
G3 7 (17.5)Journal of Experimental & Clinical Cancer Research 2008, 27:53 http://www.jeccr.com/content/27/1/53
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Discussion
NF-κB activation plays a role in the regulation of more
than 400 gene product expressions associated with
inflammation, cell survival, proliferation, invasion and
angiogenesis [3,7]. The NF-κB family contains five genes,
which are NF-κB1 (p59/p105), NF-κB2 (p52/p100), Re1A
(p65), c-Rel and RelB. The NF-κB dimers have been
shown to be present in the cytoplasm of many cells in an
inactive state. NF-κB activation can be initiated by the
stimuli of various signaling pathways like cytokines,
growth factors and tyrosine kinases [4]. Various molecular
mechanisms have been described for the activation of NF-
κB. While the classical or canonical NF-κB pathway
involves the Re1A or the c-REL dimers together with p50,
the alternative pathway involves Re1B and p100 subunits.
Tumor cells have such physiology that they can grow rap-
Strong immunostaining for markers in ccRCC Figure 1
Strong immunostaining for markers in ccRCC. Expression of NF-κB in malignant and non-malignant renal tissue (A), 
high-level immunstaining for NF-κB (B), VEGF (C), EGFR (D), bcl-2 (E), and p53 (F). Note that increased NF-κB expression is 
associated with increased VEGF, EGFR, bcl-2 and p53.Journal of Experimental & Clinical Cancer Research 2008, 27:53 http://www.jeccr.com/content/27/1/53
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idly, avoid apoptosis, are irresponsive to growth-inhibi-
tory signals and have capability of angiogenesis, invasion
and metastasis and an infinite replicative potential.
Almost all of the genes involved in the regulation of these
processes are under the control of NF-κB transcription.
The role of NF-κB in hematological and solid tumors has
been described previously in many studies [7]. It has been
shown that there is a relation between the development
and progression of solid tumors and the subunits of NF-
κB [8]. Many studies have revealed a relation between c-
REL subunit and development of breast cancer and non-
small cell lung cancer and the role of the p50–p65 subu-
nits of NF-κB in the carcinogenesis of the breast
[12,14,15]. Furthermore, an association between the NF-
κB activation (Bc1-3/p50 complex) and development of
nasopharyngeal carcinoma has been demonstrated [33].
Nair et al. have shown an increased NF-κB nuclear immu-
nostaining in cases of cervical squamous cell carcinoma
Weak positive immunostaining for markers in ccRCC Figure 2
Weak positive immunostaining for markers in ccRCC. Expression of NF-κB in malignant and non-malignant renal tissue 
(A), low degree of immunostaning for NF-κB (B), VEGF (C), EGFR (D), bcl-2 (E), and p53 (F).Journal of Experimental & Clinical Cancer Research 2008, 27:53 http://www.jeccr.com/content/27/1/53
Page 6 of 9
(page number not for citation purposes)
and in the presence of p65-p50 activation [17]. Oya et al.
demonstrated the role of increased NF-κB activation in
the development of RCC [18]. According to the results of
their study, both the p65 and the p50 subunits of NF-κB
have an increased activation in RCC cases. Most of the
studies concerning the association between NF-κB and
tumor development usually involves the p65 subunit. In
the present study, the p50 subunit had an increased acti-
vation in ccRCCs, which supports the findings from the
literature that NF-κB has an impact in some different ways
on ccRCCs. In addition, there was a significant relation
between increased NF-κB activity and increased bc1-2,
p53, EGFR and VEGF activities.
NF-κB has an effect on apoptosis during tumor develop-
ment and progression in many ways [34]. However, recent
studies have yielded conflicting results about the effect of
NF-κB and its interaction with apoptosis [7]. Some pur-
port that NF-κB have a dual effect on apoptosis hence act-
ing as an inhibitor or an activator depending on the levels
of the p65 and cRel subunits [7]. However, the commonly
accepted view is that the activation of NF-κB leads to
apoptosis resistance. One of the pathways that NF-κB is
effective in the inhibition of apoptosis is the bc1-2 gene
family, which has an antiapoptotic effect. A few studies
conducted on RCCs have shown a role of bc1-2 increased
activity in resistance to chemotherapy in advanced stage
tumors [35]. Morais et al. demonstrated decreased antiap-
optotic bc1-2 and bcl-x protein levels in patients taking
NF-κB inhibitors for metastatic RCCs, whereas there was
not a significant change in proapoptotic bax protein levels
[36]. We found a significant correlation between the
increased NF-κB and bc1-2 expression levels. Our findings
suggest that an increase in the NF-κB activity together with
the bc1-2 activity plays a significant role in the inhibition
of apoptosis. It has been reported that apoptosis is likely
to be inhibited by NF-κB via p53 pathway. As in many
other tumors, in RCCs, mutations that may take place in
the p53 gene may impair the activity of NF-κB. There have
been some studies describing the antiapoptotic activity of
NF-κB by eliminating the wild type p53 dependent apop-
tosis [7,37]. In the present study, immunohistochemi-
cally, increased mutant p53 levels were significantly
associated with an increased expression of NF-κB. This
finding supports the idea that NF-κB prevents apoptosis
through various pathways.
Angiogenesis plays a key role in the development and pro-
gression of tumors. Angiogenesis in tumors has been
shown to be associated with the chemokines of the mac-
rophages, neutrophils and other inflammatory cells (like
monocyte chemoattractant protein, IL-8) and the growth
factors (like TNF, VEGF). NF-κB activation plays a role in
the regulation of these angiogenesis inducing products
[4,7]. VEGF, especially, is a multifunctional growth factor
family that has specific effects on endothelial cells. It
undertakes an important role in tumor growth as in many
other physiologic events. Increased VEGF activity in RCCs
indicates a poor prognosis [22-24]. Various studies have
demonstrated the inhibition of angiogenesis by the block-
age of NF-κB [38]. Arai et al. reported the decline of the
products like VEGF by the inhibition of NF-κB with dex-
amethasone administration in RCC cases [39]. The review
of the literature revealed only a few studies that reveal an
association of NF-κB with VEGF in RCCs. These studies
have demonstrated that inhibition of NF-κB decreases
VEGF levels [39,40]. We found a significant correlation
between increased VEGF and NF-κB activity in RCCs,
characterized by abundant neovascularization. Increased
VEGF, shown to be an angiogenic factor in many neo-
plasms and considered as an indication of a poor progno-
sis, has been reported to be associated with increased NF-
κB activation in RCCs, consistent with the result of the
present study.
EGFR expression is frequently associated with prolifera-
tion, invasiveness and angiogenesis in many tumors and
also considered an indicator for poor prognosis. It has
been reported that the overexpression of the EGFR in
RCCs plays a role in the development and progression of
the tumor and is frequently accompanied by high grade
tumors [41,42]. There have been a few studies showing an
association between EGFR and NF-κB in RCCs. Some
drugs used as EGFR inhibitors in RCCs act as maximum
cytotoxic agents after NF-κB blockage. An et al. demon-
strated that the signal transmission in the NF-κB activa-
tion via EGFR was performed by the
phosphotidylinositol-3-OH kinase/AKT (PI3K/AKT)
pathway [41]. They reported that blockage of NF-κB with
EGFR inhibitors adds to the maximal cytotoxic effects of
proteosome inhibitors. Similarly, the present study
showed that increased NF-κB activity was associated with
increased EGFR expression. In an effort to understand the
reasons why there is a resistance to chemotherapy, espe-
cially for the advanced stage RCCs and to eliminate this
problem, it is important to demonstrate the interaction of
NF-κB with the genes like EGFR in order to be able to
develop new modes of therapy [43-45].
Table 2: Staining Properties of NF-κB p50 subunit, EGFR, VEGF, 
bcl-2 and p53 in ccRCC
Negative Weak Moderate Strong
NF-κB 6 (15%) 5 (12.5%) 10 (25%) 19 (47.5%)
VEGF 3 (7.5%) 12 (30%) 14 (35%) 11 (27.5%)
EGFR 2 (5%) 9 (22.5%) 20 (50%) 9 (22.5%)
bcl-2 7 (17.5%) 11 (27.5%) 16 (40%) 6 (15%)
p53 27 (67.5%) 7 (17.5%) 4 (10%) 2 (5%)Journal of Experimental & Clinical Cancer Research 2008, 27:53 http://www.jeccr.com/content/27/1/53
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In some studies exploring the association between the NF-
κB activation and the tumors, a correlation between the
prognostic indicators like tumor grade and stage and NF-
κB have been demonstrated. Oya et al. found that NF-κB
activity increased in advanced stage RCCs and that NF-κB
played a role in the progression of the tumors at advanced
stages [18]. In the present study, there was a stronger
staining with NF-κB in the advanced staged ccRCC cases,
but it was not statistically significant. Moreover, Fuhr-
mans' grade, which is an important prognostic indicator
in RCCs, did not have a significant association with NF-κB
activation, either. It may be that the patients we included
in this study had mostly early stage tumors or that the
sample size was small.
In this study we used immunohistochemistry, which is a
simple reproducible method for the pathologists to con-
duct an investigation or use routinely in the investigation
of or the estimation of NF-κB, VEGF and EGFR in the
future. The review of the literature revealed only a couple
of studies concerning the evaluation of NF-κB with immu-
nohistochemical methods. NF-κB signaling pathway acti-
vation results in translocation of NF-κB subunit in the
nucleus. Therefore, NF-κB activation can be identified by
positive nuclear immunostaining of various NF-κB subu-
nits. Nuclear immunostaining has been evaluated in
many studies aiming to determine NF-κB subunits. Using
immunochemical methods, Levidou et al. in their study
on patients with gastric carcinoma evaluated both nuclear
and cytoplasmic expression of NF-κB p50 subunit [16].
They found that nuclear immunostaining was associated
with such parameters as stage and depth of invasion and
an adverse effect on survival. They noted that cytoplasmic
NF-κB immunostaining did not yield important prognos-
tic information. Cogswell et al., using immunohistochem-
ical staining, showed nuclear overexpression of p50, p52
and c-Rel subunits of NF-κB in human breast cancer [14].
They evaluated nuclear staining to show activation of NF-
κB subunits. Lessard et al. in their study on patients with
prostatic adenocarcinoma immunohistochemically
showed increased expression of nuclear p50 of NF-κB
[13]. Thornburg et al. revealed that nuclear expression of
the p50 subunit of NF-κB played a role in the develop-
ment of nasopharyngeal carcinoma [33]. In the present
study, almost all patients had cytoplasmic staining with
NF-κB in the tumoral tissues and nuclear staining was
examined for the evaluation of NF-κB activation.
Recent studies have focused on new therapeutic agents
and treatment alternatives with better antitumour effec-
tiveness on advanced RCCs [46,47]. Angiogenesis is an
extremely rare event in adults except for wound healing,
inflammation and ischemic conditions. It is required that
specific treatment alternatives targeting the angiogenetic
pathway and having minimal toxicity should be sought.
Vascularization in tumours can be inhibited by blocking
endothelial growth factors with pseudo ligands, protein
kinase inhibitors and monoclonal antibodies. Therefore,
such factors as VEGF and VEGFR have become interesting
targets of drug treatment for ccRCC. Clinical studies on
Sunitinib (Sutent), Sorafenib (Nexavar) and mTOR inhib-
itors, small molecular VEGFR inhibitors used in advanced
stage ccRCC, have rarely shown complete response to
treatment [47]. Due to mechanisms which are still
unclear, the patients receiving long-treatment become
resistant to inhibition of neoangiogenesis [48,49]. With
studies on tumour markers and development of treatment
alternatives directed towards molecular targets, it seems
that a new era for RCC treatment has started. Although
these treatment alternatives have not achieved complete
and long-term remissions, these genetic and molecular
tumour markers allow detection of biological behaviour
of each tumour and administration of specific treatments
instead of non-specific treatments. The results of this
study will contribute to development of new target mole-
cules. However, further studies are needed to determine
the role of various subunits of NF-κB in RCC and other
tumours and to develop new treatment options.
Conclusion
We found that NF-κB was associated with numerous fac-
tors in the development and progression of tumors in
ccRCCs and that increased NF-κB activity was accompa-
nied by increased bc1-2, p53, VEGF and EGFR expres-
sions. To conclude, in cancer cells, NF-κB activity is
correlated with events like proliferation, apoptosis, angio-
genesis, chemo-radioresistance and has a diagnostic and
prognostic importance. It is very important to develop
new target molecules and to establish new chemotherapic
strategies in malignancies like RCCs, which are resistant to
chemotherapy. For the antiangiogenic and EGFR inhibitor
drugs, which are lately being introduced to the therapeutic
line in the treatment of many malignancies, knowing the
effects and interactions of the molecules like NF-κB in
order to be able to predict and increase their impact, is
quite important. Moreover, NF-κB itself will be a target on
its own for the chemotherapeutic agents. Therefore, we
need to know the interaction of the various subunits of
NF-κB in different tumors and their relation with different
molecules. Establishing the subunits of NF-κB with the
simple methods as we used in this study will enable new
studies to be performed on the issue.
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